Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 24 September 2021
Accepted: 1 July 2022
First Online: 19 July 2022
Declarations
:
: Geremia Bolli has received honoraria or consulting fees for Menarini, Sanofi; and has received research support/speaker’s bureau from Sanofi. Alice Cheng has served on an advisory panel for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, HLS Therapeutics, Janssen, Merck, Medtronic, Novartis, Novo Nordisk, Sanofi; and has served as a co-investigator in trials supported by Applied Therapeutics, Boehringer Ingelheim, Sanofi, Novo Nordisk; and has received honoraria for speaking from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Janssen, HLS Therapeutics, Medtronic, Merck, Novo Nordisk, Sanofi. David Owens has received lecture fees/honoraria from Sanofi, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Roche Diagnostics.
: Not applicable.
: Not applicable.
: All authors contributed to the interpretation, writing and editing of this review and had final responsibility for approving the published version.
Free to read: This content has been made available to all.
